Abstract
Human laboratory studies have a rich history in the alcoholism field and several important determinants of alcohol use disorders have been successfully modeled under controlled laboratory conditions. Laboratory paradigms have been employed to identify biobehavioral risk markers for alcohol misuse and more recently, have been integrated with behavioral genetic, neuroimaging, and pharmacological approaches to further elucidate the neuropathophysiology of addiction and to screen for efficacious treatments. This review will address the rationale and application of human laboratory models to advance pharmacotherapy development for alcohol dependence. It is argued that when properly implemented, laboratory models may help scientists and clinicians understand mechanisms of pharmacotherapy response, which in turn may inform efforts to optimize the currently available and newly developed treatments for alcoholism. Limitations and future directions are discussed.
Keywords: Alcohol, laboratory studies, craving, pharmacotherapy, genetics
Current Pharmaceutical Design
Title: Application of Human Laboratory Models to Pharmacotherapy Development for Alcohol Dependence
Volume: 16 Issue: 19
Author(s): Lara A. Ray, Kent E. Hutchison and Molly Tartter
Affiliation:
Keywords: Alcohol, laboratory studies, craving, pharmacotherapy, genetics
Abstract: Human laboratory studies have a rich history in the alcoholism field and several important determinants of alcohol use disorders have been successfully modeled under controlled laboratory conditions. Laboratory paradigms have been employed to identify biobehavioral risk markers for alcohol misuse and more recently, have been integrated with behavioral genetic, neuroimaging, and pharmacological approaches to further elucidate the neuropathophysiology of addiction and to screen for efficacious treatments. This review will address the rationale and application of human laboratory models to advance pharmacotherapy development for alcohol dependence. It is argued that when properly implemented, laboratory models may help scientists and clinicians understand mechanisms of pharmacotherapy response, which in turn may inform efforts to optimize the currently available and newly developed treatments for alcoholism. Limitations and future directions are discussed.
Export Options
About this article
Cite this article as:
A. Ray Lara, E. Hutchison Kent and Tartter Molly, Application of Human Laboratory Models to Pharmacotherapy Development for Alcohol Dependence, Current Pharmaceutical Design 2010; 16 (19) . https://dx.doi.org/10.2174/138161210791516422
DOI https://dx.doi.org/10.2174/138161210791516422 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects
Current Cardiology Reviews Pharmacotherpy and Alzheimer’s Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach
Current Pharmaceutical Design Antileukotriene Drugs: Clinical Application, Effectiveness and Safety
Current Medicinal Chemistry Monoclonal Antobodies: Application in Radiopharmacy
Current Radiopharmaceuticals Antipsychotic and Antiepileptic Drugs in Bipolar Disorder: The Importance of Therapeutic Drug Monitoring
Current Medicinal Chemistry Challenges and Persistent Questions in the Treatment of Trichomoniasis
Current Topics in Medicinal Chemistry History Repeats Itself: Pharmacodynamic Trends in the Treatment of Anxiety Disorders
Current Pharmaceutical Design Patent Selections
Recent Patents on Cardiovascular Drug Discovery Headache in Multiple Sclerosis - Pharmacological Aspects
Current Pharmaceutical Design Monoclonal Antibodies in the Treatment of Multiple Sclerosis
Current Medicinal Chemistry Catching the Therapeutic Window of Opportunity in Early Crohn`s Disease
Current Drug Targets Therapeutic Value of Adeno Associated Virus as a Gene Therapy Vector for Parkinson's Disease – A Focused Review
Current Gene Therapy Inebilizumab-cdon: USFDA Approved for the Treatment of NMOSD (Neuromyelitis Optica Spectrum Disorder)
Current Drug Discovery Technologies Macrophage Colony-Stimulating Factor (M-CSF) in Plasma and CSF of Patients with Mild Cognitive Impairment and Alzheimers Disease
Current Alzheimer Research Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety Levodopa in Parkinson’s Disease: Current Status and Future Developments
Current Neuropharmacology Insights on the Neuromodulatory Propensity of Selaginella (Sanjeevani) and its Potential Pharmacological Applications
CNS & Neurological Disorders - Drug Targets Effect of Mandibular Repositioning Appliances on Inspiratory and Expiratory Total Air
Applied Clinical Research, Clinical Trials and Regulatory Affairs Plant Natural Products as a Potential Source for Antibacterial Agents: Recent Trends
Anti-Infective Agents in Medicinal Chemistry Chondroitin Sulfate and Glucosamine as Disease Modifying Anti- Osteoarthritis Dru gs (DMOADs)
Current Medicinal Chemistry